A novel CARD11 heterozygous missense variant in a CADINS patient
Journal of Allergy and Clinical Immunology: Global · 2025-05 · 4 (2) · 100461
DOI: 10.1016/j.jacig.2025.100461 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology: Global, 2025-05. Verfasst von Randa S AlYafie und 13 weiteren Autor:innen. Beteiligte Einrichtung: College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health Office of Extramural Research, Qatar National Research Fund.
Abstract (Originalsprache)
Background
CARD11-associated atopy with dominant interference of NF-κB signaling (CADINS) is developed as a result of heterozygous loss-of-function variants in CARD11 that function as strong dominant-negative alleles. In lymphocytes, CARD11 encodes a scaffold protein that links activation of the antigen receptor with downstream signaling. Patients with CADINS generally experience severe atopic dermatitis, asthma, recurrent pneumonia and other upper respiratory tract infections, skin infections, and allergies to a variety of dietary and environmental antigens. Additionally, patients experience elevated levels of serum IgE, but low to normal levels of other immunoglobulin types.
Objective
We performed genetic diagnosis of a patient of nonconsanguineous descent presenting at 11 years of age with severe atopic dermatitis, asthma, food allergy, skin and recurrent infections, and an extremely elevated level of serum IgE.
Methods
We performed whole genome sequencing of samples obtained from the patient and his entire family.
Results
Clinical, laboratory, genetic, and functional findings suggested CADINS. Genetic evaluation revealed a novel heterozygous missense variant (c.2913C>G, p.Cys971Trp) in the CARD11 gene as the potential underlying defect. Expression of CARD11 variant-stimulated constitutive NF-κB activity in T-cell lines demonstrated both loss-of-function and dominant-negative activity.
Conclusion
A novel germline heterozygous missense variant (c.2913C>G) in CARD11 potentially leads to CADINS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.
- Research Department, Sidra Medicine, Doha, Qatar.
- Department of Allergy and Immunology, Sidra Medicine, Doha, Qatar.
- Hamad Medical Corporation, Doha, Qatar.
- Department of Pharmacology & Molecular Therapeutics, Uniformed Services, University of the Health Sciences, Bethesda, Md.
- The Rockefeller University, New York, NY.
Förderung
- NIAID NIH HHS
- National Institutes of Health Office of Extramural Research
- Qatar National Research Fund
- National Institutes of Health
- Hamad Bin Khalifa University
Zitieren
APA
AlYafie, R. S., Adeli, M., Velayutham, D., Bougarn, S., Ata, M., Al-Ali, F., Chin-Smith, E., Bauman, B. M., Snow, A. L., Boisson, B., Marr, N., van Panhuys, N., Guennoun, A., & Jithesh, P. V. (2025). A novel CARD11 heterozygous missense variant in a CADINS patient. Journal of Allergy and Clinical Immunology: Global, 4(2), 100461. https://doi.org/10.1016/j.jacig.2025.100461
Vancouver
AlYafie RS, Adeli M, Velayutham D, Bougarn S, Ata M, Al-Ali F, et al. A novel CARD11 heterozygous missense variant in a CADINS patient. Journal of Allergy and Clinical Immunology: Global. 2025;4(2):100461. doi:10.1016/j.jacig.2025.100461
BibTeX
@article{AlYafie2025,
author = {AlYafie, Randa S and Adeli, Mehdi and Velayutham, Dinesh and Bougarn, Salim and Ata, Manar and Al-Ali, Fatima and Chin-Smith, Evonne and Bauman, Bradly M and Snow, Andrew L and Boisson, Bertrand and Marr, Nico and van Panhuys, Nicholas and Guennoun, Andrea and Jithesh, Puthen Veettil},
title = {A novel CARD11 heterozygous missense variant in a CADINS patient},
journal = {Journal of Allergy and Clinical Immunology: Global},
year = {2025},
volume = {4},
number = {2},
pages = {100461},
doi = {10.1016/j.jacig.2025.100461}
}
EUVIMED